Overview

Suvorexant on Sleep Disturbance in Patients With Chronic Insomnia and Suboptimally Controlled Type 2 Diabetes

Status:
Active, not recruiting

Trial end date:
2021-09-15

Target enrollment:

Participant gender:

Summary

The investigators aim to determine the effect of suvorexant on subjective total sleep time (TST) in suboptimally controlled Type 2 diabetics with chronic insomnia in a randomized placebo-controlled trial for 3 months.

Phase:

Phase 4

Details

Lead Sponsor:

Massachusetts General Hospital

Treatments:

Suvorexant